Current Pathophysiological and Therapeutic Options for Children with Hutchinson Gilford Syndrome

References (71)

1. 1 Recurrent de novo point mutations in lamin A cause Hutchinson–Gilford progeria syndrome [DOI]
2. 2 Lamin A Truncation in Hutchinson-Gilford Progeria [DOI]
3. 3 The next generation of CRISPR–Cas technologies and applications [DOI]
4. 4 Autophagy in healthy aging and disease [DOI]
5. 5 In vivo base editing rescues Hutchinson–Gilford progeria syndrome in mice [DOI]
6. 6 Towards frailty biomarkers: Candidates from genes and pathways regulated in aging and age-related diseases [DOI]
7. 7 Chemical Inhibition of NAT10 Corrects Defects of Laminopathic Cells [DOI]
8. 8 Hutchinson-Gilford Progeria Syndrome: A premature aging disease caused by LMNA gene mutations [DOI]
9. 9 Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth [DOI]
10. 10 Pleiotropic effects of mitochondria in aging [DOI]
11. 11 Targeting of NAT10 enhances healthspan in a mouse model of human accelerated aging syndrome [DOI]
12. 12 Role of progerin-induced telomere dysfunction in HGPS premature cellular senescence [DOI]
13. 13 A genome-wide CRISPR-based screen identifies KAT7 as a driver of cellular senescence [DOI]
14. 14 Development of a CRISPR/Cas9-based therapy for Hutchinson–Gilford progeria syndrome [DOI]
15. 15 Identification of mitochondrial dysfunction in Hutchinson–Gilford progeria syndrome through use of stable isotope labeling with amino acids in cell culture [DOI]
16. 16 DNA repair defects and genome instability in Hutchinson–Gilford Progeria Syndrome [DOI]
17. 17 Clinical Aspects of Transporter‐Mediated Drug–Drug Interactions [DOI]
18. 18 Lonafarnib: First Approval [DOI]
19. 19 Ghrelin and Growth Hormone Secretagogue Receptor Expression in Mice during Aging [DOI]
20. 20 Targeting Isoprenylcysteine Methylation Ameliorates Disease in a Mouse Model of Progeria [DOI]
21. 21 Methylene blue alleviates nuclear and mitochondrial abnormalities in progeria [DOI]
22. 22 Progerin accumulation in nucleus pulposus cells impairs mitochondrial function and induces intervertebral disc degeneration and therapeutic effects of sulforaphane [DOI]
23. 23 Pathophysiology of the anorexia of aging [DOI]
24. 24 Hutchinson–Gilford Progeria Syndrome: A Premature Aging Disease [DOI]
25. 25 Inhibition of the acetyltransferase NAT10 normalizes progeric and aging cells by rebalancing the Transportin-1 nuclear import pathway [DOI]
26. 26 Ghrelin: A link between ageing, metabolism and neurodegenerative disorders [DOI]
27. 27 Protective Effects of Ghrelin on Fasting-Induced Muscle Atrophy in Aging Mice [DOI]
28. 28 Congenital Absence of Hair and Mammary Glands with Atrophic Condition of the Skin and its Appendages in a Boy Whose Mother Had Been Almost Wholly Bald from Alopecia Areata from the Age of Six [DOI]
29. 29 The Defective Nuclear Lamina in Hutchinson-Gilford Progeria Syndrome Disrupts the Nucleocytoplasmic Ran Gradient and Inhibits Nuclear Localization of Ubc9 [DOI]
30. 30 Ablations of Ghrelin and Ghrelin Receptor Exhibit Differential Metabolic Phenotypes and Thermogenic Capacity during Aging [DOI]
31. 31 Defective nuclear import of Tpr in Progeria reflects the Ran sensitivity of large cargo transport [DOI]
32. 32 The Role of Ghrelin and Ghrelin Signaling in Aging [DOI]
33. 33 A nuclear lamina‐chromatin‐Ran GTPase axis modulates nuclear import and DNA damage signaling [DOI]
34. 34 Adenosine-to-Inosine Editing of Vasoactive MicroRNAs Alters Their Targetome and Function in Ischemia [DOI]
35. 35 Progerinin, an optimized progerin-lamin A binding inhibitor, ameliorates premature senescence phenotypes of Hutchinson-Gilford progeria syndrome [DOI]
36. 36 Enhanced nuclear protein export in premature aging and rescue of the progeria phenotype by modulation of CRM1 activity [DOI]
37. 37 Hutchinson-Gilford progeria syndrome: Rejuvenating old drugs to fight accelerated ageing [DOI]
38. 38 Par-4-dependent p53 up-regulation plays a critical role in thymoquinone-induced cellular senescence in human malignant glioma cells [DOI]
39. 39 Function of the Nuclear Transport Machinery in Maintaining the Distinctive Compositions of the Nucleus and Cytoplasm [DOI]
40. 40 A small-molecule ICMT inhibitor delays senescence of Hutchinson-Gilford progeria syndrome cells [DOI]
41. 41 Paclitaxel mitigates structural alterations and cardiac conduction system defects in a mouse model of Hutchinson–Gilford progeria syndrome [DOI]
42. 42 Prelamin A processing, accumulation and distribution in normal cells and laminopathy disorders [DOI]
43. 43 iTRAQ-based analysis of progerin expression reveals mitochondrial dysfunction, reactive oxygen species accumulation and altered proteostasis [DOI]
44. 44 Emerging candidate treatment strategies for Hutchinson-Gilford progeria syndrome [DOI]
45. 45 Telomere replication—When the going gets tough [DOI]
46. 46 Ultraviolet radiation-induced differential microRNA expression in the skin of hairless SKH1 mice, a widely used mouse model for dermatology research [DOI]
47. 47 miR-376a-3p and miR-376b-3p overexpression in Hutchinson-Gilford progeria fibroblasts inhibits cell proliferation and induces premature senescence [DOI]
48. 48 CRISPR base editor treats premature-aging syndrome [DOI]
49. 49 Nuclear protein export pathway in aging therapeutics [DOI]
50. 50 Precision Medicine and Progress in the Treatment of Hutchinson-Gilford Progeria Syndrome [DOI]
51. 51 Mitochondria in health, disease, and aging [DOI]
52. 52 Accelerated cerebromicrovascular senescence contributes to cognitive decline in a mouse model of paclitaxel (Taxol)‐induced chemobrain [DOI]
53. 53 FDA approval summary for lonafarnib (Zokinvy) for the treatment of Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathies [DOI]
54. 54 Hutchinson-Gilford Progeria Syndrome: Cellular Mechanisms and Therapeutic Perspectives [DOI]
55. 55 p300 nucleocytoplasmic shuttling underlies mTORC1 hyperactivation in Hutchinson–Gilford progeria syndrome [DOI]
56. 56 The Molecular and Cellular Basis of Hutchinson–Gilford Progeria Syndrome and Potential Treatments [DOI]
57. 57 Mitophagy defect mediates the aging‐associated hallmarks in Hutchinson–Gilford progeria syndrome [DOI]
58. 58 Inhibition of N-Acetyltransferase 10 Suppresses the Progression of Prostate Cancer through Regulation of DNA Replication [DOI]
59. 59 miR-140-5p and miR-140-3p: Key Actors in Aging-Related Diseases? [DOI]
60. 60 Chromatin phase separation and nuclear shape fluctuations are correlated in a polymer model of the nucleus [DOI]
61. 61 Rescue of Mitochondrial Function in Hutchinson-Gilford Progeria Syndrome by the Pharmacological Modulation of Exportin CRM1 [DOI]
62. 62 Ghrelin delays premature aging in Hutchinson‐Gilford progeria syndrome [DOI]
63. 63 Progerinin, an Inhibitor of Progerin, Alleviates Cardiac Abnormalities in a Model Mouse of Hutchinson–Gilford Progeria Syndrome [DOI]
64. 64 Doxycycline decelerates aging in progeria mice [DOI]
65. 65 Revealing the pharmacological effects of Remodelin against osteosarcoma based on network pharmacology, acRIP-seq and experimental validation [DOI]
66. 66 The farnesyl transferase inhibitor (FTI) lonafarnib improves nuclear morphology in ZMPSTE24-deficient fibroblasts from patients with the progeroid disorder MAD-B [DOI]
67. 67 Biomarker potential of hsa-miR-145-5p in peripheral whole blood of manic bipolar I patients [DOI]
68. 68 The Nuclear Envelope in Ageing and Progeria [DOI]
69. 69 Ablation of Ghrelin Receptor Mitigates the Metabolic Decline of Aging Skeletal Muscle [DOI]
70. 70 Elevated Ghrelin Promotes Hippocampal Ghrelin Receptor Defects in Humanized Amyloid-β Knockin Mice During Aging [DOI]
71. 71 Molecular Basis for RNA Cytidine Acetylation by NAT10 [DOI]

Cited by 2

Showing 1 of 2 known citations — external sources report more than can currently be individually listed.